Redwood City, CA, September 29, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that Robert Brown has joined the company as Chief Financial Officer, starting immediately. Mr. Brown’s
Gynesonics Announces FDA Clearance of Next Generation Sonata System
The Only Transcervical, Incisionless System for Radiofrequency Ablation of Fibroids Provides New Benefits through Features Such as Increased Range of Ablation Sizes, a New User Interface, and Validation of Additional Low Temperature Hospital Reprocessing Systems Redwood City, CA, September 16, 2021
Gynesonics Announces Anthem, the Second Largest Healthcare Payer in the U.S., Issues Medical Necessity Coverage for the Treatment of Symptomatic Uterine Fibroids with the Sonata Procedure
Anthem’s decision significantly increases nationwide access for Sonata Redwood City, CA, September 14, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced Anthem, Inc., the largest managed health
Gynesonics Announces Expert Group of European Gynecologic Surgeons Publishes Consensus on the Broad Use of the Sonata Technology in a New Treatment Strategy for Symptomatic Fibroids
The Combined Clinical Experience of Over 1000 Sonata Procedures, Across Three Countries, Drives New Recommendation for Sonata as a First Line Therapy for Fibroid Treatment Redwood City, CA, August 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
Gynesonics Announces Positive Payer Coverage Issued by Blue Cross Blue Shield of Florida (Florida Blue) for the Sonata Treatment
Florida Blue is the Largest Healthcare Payer in that State Redwood City, CA, June 11, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today Blue Cross Blue Shield of Florida (Florida Blue) has
Gynesonics Appoints David Pacitti to Board Chair
Current President and Head of Siemens Healthineers in The Americas Brings Strong Commercial Experience to the Board of Directors Karen Talmadge, Ph.D., Remains as Independent Board Member, Retaining Key Strengths and Experience for Gynesonics Redwood City, CA, June 7, 2021 – Gynesonics®, a
Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System
The national policy covers approximately 15 million lives in 48 states and Washington D.C. for this minimally invasive, uterine-preserving and incision-free treatment Redwood City, CA, June 3, 2021 – Gynesonics®, a women’s healthcare company focused on the development of minimally invasive
New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option
Additionally, an expert physician panel in Europe reached consensus and published a new recommended fibroid treatment algorithm with transcervical radiofrequency ablation (Sonata) at the forefront Redwood City, CA, June 1, 2021 – Gynesonics®, a women’s healthcare company focused on the development